CC BY
42
THE ROLE OF IMMUNOLOGICAL MEMORY IN ESTABLISHING ANTITUMOR IMMUNITY IN PATIENTS WITH OVARIAN CANCER UNDERGOING NEOADJUVANT THERAPY
Zlatnik EYu1 ^ Nerodo GA2, Ardzha AYu2, Seliutina ON1, Bondarenko ES1
1 Laboratory for Immunophenotyping of Tumors,
Rostov Research Institute of Oncology, Rostov-on-Don, Russia
2 Department of Gynecologic Oncology,
Rostov Research Institute of Oncology, Rostov-on-Don, Russia
Understanding the role of immunological memory mediated by T-lymphocytes in patients with malignant tumors is a pressing issue. This study aimed to assess the contribution of memory T-cells to antitumor immunity in patients with ovarian cancer undergoing neoadjuvant chemoimmunotherapy with recombinant interferon-gamma (rIFNy). Quantification of central {Tari) and effector (Tem) memory T-cells (Tm), as well as naive T-lymphocytes (Th0), was done using flow cytometry. Compared to healthy females, untreated cancer patients were found to have more Tm and less Th0 cells in their blood CD4+ and CD8+ T-cell subpopulations. In cancer patients, Tm cells accumulated in the ascitic fluid, exceeding 7.7 times the number of CD4+ Th0 cells and 6.5 times the number of CD8+ Th0 cells, with Tem prevailing over Tcm. After chemotherapy with rIFNy, blood Th0 decreased in cancer patients, while Tcm dominated the CD8+ Tm subpopulation both in the blood and ascitic fluid. Tem cells were a prevalent cell type in patients who received chemotherapy without interferon-gamma. Decreased Th0 and Tcm prevalence were a positive sign accompanied by a good response to treatment, including lower relapse rates (46.7 % vs. 80 % in controls) and a longer relapse-free period (17.5 ± 1.6 vs. 11.3 ± 1.5 months in controls). Therefore, we conclude that chemoimmunotherapy alters proportions of T-cell subpopulations in the blood and ascitic fluid of patients with ovarian cancer, with Tcm cells prevailing over Tem, which may be one of the mechanisms of rIFNy (Ingaron) action.
Keywords: ovarian cancer, ascitic fluid, blood, flow cytometry, lympocytes, memory T-cells, Tcm, Tem, Th0, interferon-gamma
Correspondence should be addressed: Elena Zlatnik
14-ya liniya, d. 63, Rostov-on-Don, Russia, 344037; elena-zlatnik@mail.ru
Recieved: 22.09.2017 Accepted: 30.09.2017
РОЛЬ ИММУНОЛОГИЧЕСКОЙ ПАМЯТИ В ФОРМИРОВАНИИ ПРОТИВООПУХОЛЕВОГО ИММУНИТЕТА У БОЛЬНЫХ РАКОМ ЯИЧНИКОВ НА ЭТАПЕ НЕОАДЪЮВАНТНОГО ЛЕЧЕНИЯ
Е. Ю. Златник1 Г. А. Неродо2, А. Ю. Арджа2, О. Н. Селютина1, Е. С. Бондаренко1
1 Лаборатория иммунофенотипирования опухолей,
Ростовский научно-исследовательский онкологический институт, Ростов-на-Дону
2 Отделение онкогинекологии,
Ростовский научно-исследовательский онкологический институт, Ростов-на-Дону
Изучение роли иммунологической памяти, опосредованной Т-лимфоцитами, при злокачественных опухолях и их лечении — актуальная научная задача. Целью исследования была оценка роли Т-клеток иммунологической памяти в формировании противоопухолевого иммунитета у больных раком яичников на этапе неоадъювантного лечения, включающего химиоиммунотерапию с применением рекомбинантного интерферона-гамма (рИФНу). Методы: проточная цитометрия для определения центральных (Гсп) и эффекторных (Tem) Т-клеток памяти (Tm) и наивных Т-лимфоцитов (Th0). Результаты: в крови больных по сравнению с донорами обнаружено высокое (Tm) и низкое (Th0) содержание Т-клеток среди CD4+ и CD8+ субпопуляций. В асцитической жидкости происходило накопление Tm, превышающих количество Th0 в 7,7 раза в субпопуляции CD4+ и в 6,5 раза в субпопуляции CD8+, в которой Tem преобладали над Tom. После химиотерапии с препаратом рИФНу в крови больных выявлено снижение уровня Th0, в крови и в асцитической жидкости — преобладание Toti среди CD8+ Tm, а у больных, получавших химиотерапию без иммунотерапии, преобладали Tem. Данные различия были расценены как благоприятные, поскольку сопровождались положительной клинической динамикой: меньшей частотой рецидивирования (46,7 против 80 % в контроле) и более длительным безрецидивным периодом (17,5 ± 1,6 против 11,3 ± 1,5 мес. в контроле). Таким образом, химиоиммунотерапия вызывает перераспределение субпопуляций Т-клеток в крови и в асцитической жидкости при раке яичников в сторону преобладания Toti над Tem, что может быть одним из механизмов действия препарата «Ингарон» (рИФНу).
Ключевые слова: рак яичников, асцитическая жидкость, кровь, проточная цитометрия, лимфоциты, Т-клетки памяти, Toti, Tem, наивные Т-лимфоциты, интерферон-у
123 Для корреспонденции: Златник Елена Юрьевна
ул. 14-я линия, д. 63, г Ростов-на-Дону, 344037; elena-zlatnik@mail.ru
Статья получена: 22.09.2017 Статья принята к печати: 30.09.2017
Rapid development of cell technologies promises advancements in antitumour treatment methods. One of those methods is adoptive immunotherapy that implies application of ex vivo activated lymphocytes of peripheral blood and tumor microenvironment lymphocytes (LAK- and TIL-cells), CIK-lymphocytes, DC-vaccination, etc. [1]. In recent years, a number of studies highlighted efficiency of CAR therapy against certain types of tumors [2].
Nevertheless, adoptive immunotherapy in cancer patients often fails to deliver on expectations, which leads to clinicians abandoning the approach both as alternative to chemotherapy or as a complement to it [1]. Such anti-cancer strategies often fail because of immunosuppressive mechanisms active in cancer patients' bodies, the mechanisms that cause imbalance and dysfunction in various subpopulations of lymphocytes, including lymphocytes powering immunological memory. Immunological memory is not a newly discovered phenomenon. It belongs to the adaptive immunity system that includes T- and B-cell links. Memory lymphocytes play an important part in opposing any chronic pathology. As for tumors, of special importance is the immunological memory mediated by T-lymphocytes. In such cases, researchers pay close attention to CD8+ cells, since, compared to their naive counterparts, those memory cells show a much higher incidence of specific cytotoxic T-lymphocytes recognizing tumor-associated antigens [3]. As the example of melanoma melan-A tetramer shows, in cancer patients, naive T-lymphocytes (Th0) and memory T-cells (Tm) respond ex vivo stimulation with tumor antigen differently; CD45RA+CCR7+ cells do respond and CD45RO+CCR7- do not [4, 5]. Some authors believe the level of CD8+ memory cells in a colorectal cancer tumor and other solid tumors is a key factor for survival of patients [6].
Adoption of lymphocytes immunophenotyping methods in the late 20th century lead to discovery of heterogeneity of Tm lymphocytes subpopulation; as is known now, its subdivision depends on the expression of adhesive, chemokine, costimulatory receptors, on the ability to produce cytokines and the response to them, the ability to penetrate through endothelium and other characteristics. These expressions, abilities and characteristics allowed determining basic subpopulations of Tm: central (Tcm) and effector (Tem). Characteristic for the phenotype of these cells is the CD45RO expression and no CD45RA expression, as well as presence of CCR7, CD62L, CD27 and CD28 on Tcm receptors. As for the Tem cells, they have no CCR7, CD62L and CD28 expression and do show that for CD27 [7]. Th0 boast high CCR7, CD62L, CD27, CD28 and CD45RA expression and no CD45RO. Thus, immunophenotyping with a minimal panel of monoclonal antibodies CD62L, CD45RA and CD45RO allows associating T-lymphocyte to a Th0, Tcm or Tem subpopulation.
Chronic antigenic stimulation alters Th0, which results in not just the aforementioned change in their immunophenotype but also in suppression of proliferation and decreased survival rate, as well weaker response to homeostatic cytokines (IL-7, IL-15) and ability to produce IL-2. At the same time, effector functions, cytotoxicity in particular, grow. CD62L and CCR7 receptors expressed by Th0 and Tcm boost their extravasation through high endothelial venules and migration of peripheral lymph nodes to T-dependent zones, while the Tem inhabit peripheral tissues (liver, lungs) and area of inflammation/tumor [8, 9]. These properties make Tem "watchdogs" and Tcm — "guardians" on the systemic level that ensure a quick response to subsequent antigen administration [10, 11].
As for the antitumor activity of effector and central Tm, there are different opinions, but Tcm is a more popular choice [7, 9].
There is evidence proving that, although they act differently, both types of Tm cells make the antitumor protection optimal, i. e. they complement each other [12]. A number of studies states that if there are CD4+ lymphocytes among Tm, they prevent depletion of CD8+ lymphocytes [13]. Thus, it is better to use a heterogeneous mixture of those subsets [12, 13].
In addition to the basic Tm subpopulations, some researchers point to a resident subpopulation (Trm) formed by circulating CD8+ Tm, which expresses additional CD103 receptors in the nidus [14]. Various phenotypic characteristics of CD8+ Tm in different organs have also been reported. For example, peritoneal cavity normally contains only CD4+ and CD8+ effector lymphocytes, but in case of inflammation CD4+ and CD8+ Tm are also found there [14]. Retention of Tm in the microenvironment with their subsequent transformation into Tm-cells can be triggered by appearance of an antigen [15] or the "cytokine explosion" that accompanies inflammation. Earlier, researchers have described Trm cells' activity in the presence of an inflammation [16, 17], but not in tumor growth which might be a different matter.
There is a number of current research papers covering immunological aspects of ovarian cancer treatment; they are part of effort to develop new immunotherapy methods [1, 18]. Such research often leads to some unexpected findings pertaining to immunological memory cells. For example, one study describes a minor subpopulation of Tm expressing B-cell receptor CD20+ together with IFNy+ and CD8+ [19], which allows assuming its tumor growth suppressing qualities.
Normally, Tcm cells dominate in CD4+ subpopulation; the same is true for Tem in CD8+ subpopulation [11]. The numbers of these cells are different in lymphoid and non-lymphoid organs, and their phenotypic and functional characteristics may differ depending on microenvironment [14].
The immune response to a tumor is both system-wide and local, it activates various cell-based and cell-related factors and also their soluble products [18]. However, it is believed that immunocompetent cells and cytokines present in the tumor's microenvironment can both contribute to this tumor's regression and stimulate its growth, especially at advanced stages [20-23].
Treatment of ovarian cancer (OC) remains one of the biggest challenges for oncologists [24]. According to the available data, OC is the fifth most common cancer. Despite the continuous improvement of diagnostic and treatment methods, it still is the deadliest one. Although chemotherapy is quite efficient against OC, the tumor rarely disappears completely and is prone to recur frequently and early. Today, a combination of surgery and chemotherapy is a standard approach to treating OC at III-IV stages. However, currently it is impossible to make full use of cytoreductive operation due to technical difficulties associated with the spread of tumor. In case surgery is not possible, the first stage of treatment is neoadjuvant chemotherapy, and after the surgery comes adjuvant chemotherapy. The most popular combination for a chemotherapy course is Paclitaxel and Carboplatinum with a 3-week interval [25].
Ingaron, recombinant interferon-gamma (rIFNy) injectable preparation developed by Russian scientists, aims to stimulate cellular immunity and produces antiviral, antiproliferative and immunomodulating effects [26]. Its antitumor activity derives from the ability to activate natural killers (NK cells), cytotoxic T-lymphocytes and macrophages. Given together with cytostatics, Ingaron helps to decrease the resistance of tumor cells to chemotherapy and thus to make the treatment significantly more effective [27]. Research showed Ingaron to be an efficient medication against cervical cancer, breast cancer,
lung cancer, melanoma, colorectal cancer. The preparation worked even when the stages were advanced [28].
This study aimed to assess the contribution of memory T-cells to antitumor immunity in patients with ovarian cancer undergoing neoadjuvant chemoimmunotherapy with recombinant interferon-gamma (rIFNy)
METHODS
The study was conducted from 2013 to 2017 at the Department of Gynecologic Oncology, and Laboratory for Immunophenotyping of Tumors, Rostov Research Institute of Oncology (RRIO), Rostov-on-Don, Russia. 30 OC patients aged 34 to 77 underwent examination; the mean age was 54.9 ± 1.3 years. All patients had their tumors detected for the first time. The average duration of a case history was 7 months. All patients voluntarily signed informed consent forms, all examinations followed ethical principles set by the Declaration of Helsinki (2013). Ethical committee of RRIO approved the study by the protocol no. 24 of November 23, 2012.
The inclusion criteria were: 18 years old or older; ascitic form, III-IV stage OC verified cytologically or morphologically; no previous special treatment courses.
The exclusion criteria were: expressed comorbidity (previous myocardial infarction, decompensated heart disease, diabetes mellitus); chemotherapy, radiation therapy, surgery, immunotherapy courses underwent before treatment in the context of the study; metastatic lesions in the central nervous system; pregnancy and lactation; any reasons preventing regular treatment and monitoring sessions.
The patients were divided into 2 groups, 15 patients in each. For group 1 (treatment group) chemotherapy was combined with rIFNy immunotherapy (ChIT), group 2 (control group) got chemotherapy (ChT) only.
Comparative analysis of the groups revealed that both had 11 (73.3 %) stage III OC patients and 4 (26.7 %) stage IV OC patients. The differences were statistically insignificant (p > 0.05). The majority of patients were aged 50-59 years: 5 (33.3 %) in the treatment, 6 (40.0 %) in the control group. No statistically significant difference detected. ECOG-WHO scale was applied to assess the general condition of patients; most scored 2 points (8 (53.3 %) and 9 (60.0 %) patients in treatment group and control group, respectively). The differences were not statistically significant. Thus, age, OC stages and general condition were identical for both groups, which allows making the comparative analysis.
The comparison group consisted of 20 practically healthy women of the same age who had blood samples taken.
The patients were examined as their treatment progressed, before and 3 weeks after ChT (15 patients) and ChIT (15 patients). The 3-week interval matched that between treatment courses. The patients received two to three courses of polychemotherapy: Carboplatinum (AUC-6), intravenously (dropping), Paclitaxel 175 mg/m2 intravenously (dropping), 21 days between the courses. ChIT regimen was as follows: rIFNy (Ingaron by Pharmaclone, Russia) injected intramuscularly, 500,000 IU on day 1, 1,000,000 IU on days 2, 3 and 5, and day 4 was for Paclitaxel + Carboplatinum (polychemotherapy). Age, OC stages and general conditions were identical for both groups.
Further, all patients underwent surgery depending on the results of the treatment. It could be total hysterectomy with salpingo-oophorectomy, omentum resection or extirpation, salpingo-oophorectomy. Post-operation, treatment group
patients received adjuvant ChIT: Ingaron, intramuscularly, same regimen started on the 9th day. The patients had 2 Ingaron cycles and then 4 chemotherapy cycles, which made the entire adjuvant treatment course included 6 cycles. Control group patients received 6 ChT cycles.
Complete or partial regression and the general effect (tumor regression and stabilization) and progression values as defined by WHO were criteria for assessment of the effect produced by neoadjuvant therapy.
The post-treatment follow-up period was 3 years, with tumor recurrence time registered.
Blood and ascitic fluid (AF) samples were taken before the treatment and at its stages. The total number of blood samples examined was 98, number of AF samples equaled 47.
Blood lymphocytes and AF flow cytofluorimetry. The device used for the purpose was BD FACSCanto II flow cytometer (Becton Dickinson, USA). It features two lasers emitting at 488 nm and 633 nm (fluorophores excitation wavelengths) and allows using up to 6 monoclonal antibodies in one tube simultaneously. Monoclonal antibodies were conjugated with the following fluorochromes: FITC, PE, PerCP-Cy5.5, PE-Cy7, APC, APC-Cy7. The cytometer was set up with the help of standard BD FACS 7-color setup beads (BD Biosciences, USA).
Sample preparation and immunophenotypic staining. To assess expression of receptors, researchers resorted to immunophenotypic staining. It was done with fluorescently-labeled antibodies as prescribed by the protocol supplied by the manufacturer. For each examination, 2 tubes with the following sets of monoclonal antibodies BD Multitest (Becton Dickinson, USA) were used:
1. CD45RA FITC/CD45RO PE/CD3 PerCP/CD4 APC (cat. #340571) or CD45RA FITC/CD45RO PE/CD3 PerCP/CD8 APC (cat. #340574);
2. CD45RA FITC/CD62L PE/CD3 PerCP/CD4 APC (cat. #340977).
This panel of antibodies allows to count the content of Th0, Tcm and Tem (CD62L+CD45RA+CD45RO-, CD62L+CD45RA-CD45RO+ and CD62L-CD45RA-CD45RO+ respectively) among CD4+ and CD8+ Tm subpopulations. At least 50,000 cells were accumulated in each sample for data analysis.
Gating tactics and data analysis. The lymphocyte region was determined with the help of Dot Plot chart by direct (relative cell size) and lateral (cell structure) light scattering parameters. The share of T-helpers and cytotoxic T-lymphocytes in the overall lymphocytes population was calculated within this range by markers CD3, CD4 and CD8. Next, we analyzed the share of T-lymphocytes with phenotypes CD4+CD45RO+ CD45RA-, CD8+CD45RO+CD45RA-, CD4+CD45RA+CD62L+, CD8+CD45RA+CD62L+ in the populations of T-helpers and cytotoxic T-lymphocytes. For each sample, Tm/Th0 coefficients were calculated for CD4+ and CD8+ subpopulations. Tcm and Tem levels were taken as a percentage of the number of Tm belonging to CD4+ and CD8+ subpopulations, then the Tem/ Tcm coefficient was calculated. Fig. 1 and 2 show examples of blood and AF flow cytofluorimetry results.
Mathematical and statistical processing methods. BD FACSDiva Software (Becton Dickinson, USA) did mathematical processing of the data. Statistica 8.0 for Windows and MS Excel were the tools that enabled the results analysis and statistical processing. The threshold of statistical significance of differences was p < 0.05. The Wilcoxon test was also used; the x2 fitting criterion helped to assess reliability of differences between frequency of development of total and overall effect and frequency of recurrence.
(C)
(D)
(E)
(F)
(G)
Fig. 1. Peripheral blood Tm, flow cytometry: (A) — lymphocyte region among blood cells; (B) — T-lymphocytes population; (C) — distribution of CD4 and CD8; (D) — distribution of CD45RA and CD45RO after logical restriction by CD4; (E) — distribution of CD45RA and CD45RO after logical restriction by CD8; (F) — distribution of CD45RA and CD62L after logical restriction by CD4; (G) — distribution of CD45RA and CD62L after logical restriction by CD8
RESULTS
Tables 1-4 and in Fig. 3 and 4 show the results of the study. We found some differences in content of Tm and Th0 lymphocytes in biological fluids samples. As seen in Table 1, blood of OC patients has a higher level of Tm among CD3+CD4+ cells and a lower level of Th0 among CD3+CD8+ cells compared to those seen in healthy women; the difference is statistically significant (p < 0.05). Comparison of levels of Tm in blood and AF of OC patients revealed that these cells are much more common in AF (p < 0.05). In contrast, the levels of Th0 in AF were
statistically significantly lower when compared to those seen in the patients's blood (p < 0.05) (Table 1).
There were no statistically significant differences between CD4+ and CD8+ cell levels in blood and AF, although levels of lymphocytes and monocytes in AF significantly exceeded those seen in blood. Despite the significantly higher level of lymphocytes in AF (52.4 ± 5.5 compared to 17.4 ± 2.7 % in patients' blood), the contents of their main subpopulations in these biological fluids were not statistically different: the level of CD4+ cells in blood was 49.2 ± 3.1 %, that in the AF — 48.7 ± 3.2 %; CD8+ levels were 18.4 ± 2.7 and 22.6 ± 3.3 %,
Fig. 2. AF Tm, flow cytometry: (A) — lymphocytes region; (B) — T-lymphocytes population; (C) — distribution of CD4 and CD8; (D) — distribution of CD45RA and CD45RO after logical restriction by CD4; (E) — distribution of CD45RA and CD45RO after logical restriction by CD8; (F) — the distribution of CD45RA and CD62L after logical restriction by CD4; (G) — distribution of CD45RA and CD62L after logical restriction by CD8
respectively. The CD4+/CD8+ index for AF was also on par with that for blood of patients, i. e. there were no statistically significant differences there. However, the ratio of Tm/Th0 found in both T-cell subpopulations was significantly higher in AF of patients than in their blood (7.7 ± 1.0 vs. 2.9 ± 0.5 for CD4+ cells and 6.5 ± 1.3 vs. 2.1 ± 0.3 for CD8+ cells; in both cases, p < 0.05). This means there are markedly more Tm than Th0 in the tumor nidus than in the peripheral blood.
We also found some differences in content of Tm subpopulations in the examined biological fluids (Table 2).
Table 2 shows that Tem levels among subpopulations of CD4+ and CD8+ cells in AF are statistically significantly higher than those in blood of patients and in blood of healthy women
(p < 0.05). As for the content of Tcm, the differences between AF of patients and blood of healthy women were found for CD8+ only. It is interesting that there were no statistically significant differences in the studied subpopulations in blood of patients and healthy individuals.
Tem levels in CD4+ and CD8+ subpopulations were similar in most cases, whereas the share of Tm in CD4+ subpopulation was 2-2.3 times higher than in CD8+ subpopulation. In blood and AF samples, Tem dominated over Tcm in CD8+ cell subpopulation (over 1.0), and Tcm dominated over Tem in CD4+ subpopulation (below 1.0) (Fig. 3).
Thus, comparison of systemic and local cellular immunity indices seen in AF of OC patients showed that Tm dominate in
patients' blood when put against that of healthy women and in the patients' AF when compared to their peripheral blood. Most of the CD4+ Tm were Tcm while the majority of CD8+ Tm were Tem, which accumulated in patients' AF.
Neoadjuvant treatment lead to a complete regression of tumor in 4 patients (26.7 %) of the treatment group (ChT plus rIFNy) and in 1 (6.7 %) belonging to the control group. Assessment of the overall effect of treatment revealed statistically significant differences in data describing treatment group and control group (87.0 and 30.0 %, respectively). Only 1 patient of the control group had the tumor progressing (6.7 %).
After 2-3 cycles of neoadjuvant polychemotherapy, 12 (80.0 %) patients of the treatment group underwent full-scale surgery (total hysterectomy with salpingo-oophorectomy, omentum resection or extirpation). In control group, only 6 patients were in a state allowing this degree of intervention. The difference is significant (p < 0.05). 3 patients (20.0 %) of the treatment group had incomplete surgery that included oothecoma removal and omentum resection; in the control group, the same operations were performed on 8 patients (53.3 %), and 1 patient had a trial laparotomy.
The post-adjuvant treatment follow-up period was 3 years. Recurrence in the treatment group was 46.7 % while that in the control group was 80.0 % (7 and 12 patients, respectively). The average time of the recurrence was 17.5 ± 1.6 months and 11.3 ± 1.5 months, respectively. The differences are significant (p < 0.05).
Only the patients that had the same kind of surgery (full-scale surgery) were picked for immunological examination.
Dynamics of levels of Tm and Th0 in blood of patients from both groups can be seen in Table 3. There are some differences there. Worth a special note is the decrease of levels of naive Th0 in treatment group patients (ChT plus rIFNy), which became statistically significant by the end of the treatment (p < 0.05). In the control group, the level of these cells did not differ from the initial one during the entire follow-up period.
The Tm/Th0 ratio was growing (and reached statistical significance) in the treatment group and not in the control group (Fig. 4). Thus, the CD8+ cells Tm/Th0 ratio increased from 2.5 ± 0.5 to 3.4 ± 0.7 in patients of the treatment group, while in the control group it went down from 1.7 ± 0.3 to 1.4 ± 0.3. The difference is significant (p < 0.05). As for the
CD4+ subpopulation, the growth was 2.5-fold in the treatment group and in the control group it did not change.
During treatment, Tm content was not significantly different in treatment and control groups (Table 3), but assessment of dynamics revealed such differences in CD8+ Tm subpopulation (Table 4). In the control group, the level of Tcm gradually decreased and by the end of the treatment the difference acquired statistical significance (p < 0.05). Tem levels did not change.
ChIT that included rIFNy initially led to similar changes, but as the treatment approached completion, the volume of Tcm was greater and Tem lower in blood of treatment group patients that those in blood of control group patients (Table 4). In other words, Tcm dominated in blood of the treatment group patients and Tem were the majority in the control group patients' blood. The Tem / Tcm ratio was 2.27 ± 0.4 and 0.62 ± 0.18, respectively, p < 0.05.
The dynamics of levels of the studied subpopulations in AF could only be registered when the fluid accumulated, i. e. during the preoperative period. It was found that the Tm/Th0 levels ratio in CD4+ lymphocytes subpopulation increased from 7.7 ± 1.0 to 13.0 ± 1.5 (p < 0.05); the data describes treatment group, the increase is statistically significant. AF of patients of the same group has also shown changes in Tm CD8+ subpopulation: the level of Tem decreased (13.6 ± 4.6 compared to 42.1 ± 4.1 % in the control group, p < 0.05), and the volume of Tcm tended to increase. The total number of lymphocytes in AF after ChIT was 42.2 ± 7.8, while after ChT it was 31.1 ± 7.1 % (the differences are statistically insignificant); However, ChT lead to the reduction in their numbers compared to the initial counts, the difference here being statistically significant (52.4 ± 5.5 %, p < 0.05). Other statistically significant differences include those describing CD3+ and CD4+ cell levels: ChIT brought them up to 82.1 ± 6.3 and 57.6 ± 5.7, respectively, while ChT produced a more modest growth of 65.4 ± 6.5 % and 42.6 ± 2.5 %, respectively; in both cases p < 0.05.
Thus, the content of Tm in both CD4+ and CD8+ subpopulations in patients' AF was greater than that in their blood, while Th0 was smaller; among TmCD8+, Tem were prevalent. The study revealed that adding Ingaron (rIFNy) to a chemotherapy course, thus making it a chemoimmunotherapy
Table 1. Tm and Th0 subpopulations of CD4+ and CD8+ in blood and AF of OC patients
Samples Tm, % Th0, %
CD4+ CD8+ CD4+ CD8+
Blood of healthy women (n = 20) 55.0 ± 3.7 35.0 ± 4.3 23.4 ± 3.2 27.7 ± 3.7
Blood of OC patients (n = 30) 64.5 ± 2.3* 40.8 ± 5.1 22.4 ± 4.1 18.5 ± 2.7*
AF of OC patients (n = 30) 79.2 ± 4.0*** 57.5 ± 3.1*** 10.2 ± 1.6*** 9.5 ± 2.5***
Note. * — significant differences from blood of healthy donors (p < 0.05); ** — significant differences from blood of patients (p < 0.05). Hereinafter, in tables 2-4 reliability of the differences was calculated through the Wilcoxon test.
Table 2. Central and effector Tm with CD4+ and CD8+ phenotype in blood and AF of OC patients
Samples Tm CD4+ Tm CD8+
Tcm, % Tem, % Tcm, % Tem, %
Blood of healthy women (n = 20) 41.7 ± 2.5 17.8 ± 2.3* 17.7 ± 2.5* 24.1 ± 3.6*
Blood of OC patients (n = 30) 42.0 ± 3.1 24.8 ± 1.8* 22.0 ± 1.5 28.2 ± 3.2*
AF of OC patients (n = 30) 47.1 ± 3.3 39.8 ± 3.9 27.0 ± 2.0 42.1 ± 4.1
Note. * — significant differences from AF (p < 0.05).
2,0-
1,5-
I 1,0-
0,5-
Blood of healthy donors Blood of OC patients AF of OC patients
CD4+ Tm
Fig. 3. Tem / Tcm ratio in CD4+ and CD8+ subpopulations of memory T-cells
course, maintains the opposite dynamics of Tem and Tcm cells in patients' blood and AF.
DISCUSSION
The biological role Tm play in resisting cancer is important. The volumes and ratios of these cells can be changed through immunotherapy. Within the context of this study, we monitored and registered the levels of Tm (including Tcm, Tem) and Th0 in blood and ascitic fluid (AF) of OC patients before treatment and during chemoimmunotherapy. Earlier, we registered and described a higher content of lymphocytes (with Tm dominating) in AF of patients [29]; this study goes further and discovers the prevalence of Tem there, mostly belonging to CD8+ subpopulation. Although it is not yet possible to establish their specificity and substantiate the hypothesis of their antitumor activity, the published research data available indicate that, since the expansion of lymphocytes as part of a lymphoid infiltrate in the tumor (tumor-infiltrating lymphocytes) is clonal, antigen-specific lymphocytes should dominate in the tumor microenvironment [6]. Judging by the noticeable spread of tumor, OC patients do not develop effective immune reactions, which may be caused by some peculiar features of the tumor microenvironment. It appears that tumor cells in AF activate peritoneal macrophages and monocytes, which leads to hyperproduction of cytokines possessing pro-tumor properties [21]. AF monocytes are a potential source of type 2 macrophages that support tumor growth by autocrine production of VEGF, EGF, TGFte, IL-6, IL-8, IL-10, supported by hypoxia developing in tumor tissue [23, 30]. These same cytokines, as well as chemokines that can be produced by tumor cells, stimulate the migration of lymphocytes into the peritoneal cavity. According to the published data, there are natural T-regulatory cells (T-regs) among them, and they suppress immunity and boost tumor growth. OC patients
CD8+ Tm
have more such T-regs than healthy women [31], and the cells are much more abundant in patients' AF than in their blood [32]. They probably block the activity of T-lymphocytes, Tm in particular and other lymphocytes (NK-, CD8+) in general. Those lymphocytes, although abundant, seem to be hindered in their functions, as shown by the example of CD8+ Tm chronically stimulated in the presence of viral infections [7, 9, 33, 34]. Unlike T-regs, Tm die on schedule (apoptosis) when interacting with FasL expressed by endotheliocytes of tumor vessels; this may be one of the self-protective mechanisms the tumor has [35]. Perhaps, some measures countering local immunosuppression could allow effective inclusion of cellular factors into antitumor immune response that would rise the effectiveness of OC treatment.
As we have reported earlier, Ingaron added to a chemotherapy course causes a decrease in the level of Th0 in OC patients and otherwise positively affects their immunity [36]. In this study, we focused on learning more about Tm in OC patients. We have found that introduction of rIFNy ensures domination of Tm over Th0 in blood and AF of OC patients after chemoimmunotherapy. It also provokes redistribution of Tm CD8+ and brings around more Tcm, which is not seen in patients that receive chemotherapy without rIFNy. In part, this may be the reason behind the improved clinical effect observed when rIFNy joins chemotherapy. Although the reports published to date indicate that repeated administration of the antigen provokes proliferation and increases cytotoxicity both of Tcm and Tem (part of CD8+ T-cell subpopulation), it is believed that Tcm has these properties more pronounced and also shows a more active interaction with antigen-presenting cells, higher antigen-induced proliferation, generation of cytotoxic T-effectors and homing into secondary lymphoid organs [7, 37]. This suggests the advantage tumor-specific CD8+ Tcm have when compared to Tem as antitumor factors. Thus, the data we have received can be interpreted as one of the therapeutic mechanisms Ingaron offers against ascitic forms of OC.
Table 3. Dynamics of Tm and Th0 levels, blood of OC patients, treatment and control groups
0
Group of patients Treatment term Tm, % Th0, %
CD4+ CD8+ CD4+ CD8+
Treatment (n = 12) before treatment 65.8 ± 4.2 40.9 ± 5.2 20.5 ± 3.5* 17.2 ± 1.6*
after 2-3 ChIT cycles 64.6 ± 6.1 37.7 ± 4.5 15.7 ± 3.4 16.5 ± 2.3
after full ChIT course 72.8 ± 5.9 35.7 ± 5.1 9.7 ± 2.7 10.4 ± 2.6
control (n = 6) before treatment 66.3 ± 4.4 38.1 ± 4.7 23.6 ± 4.6 23.6 ± 5.6
after 2-3 ChT cycles 59.1 ± 7.1 31.6 ± 4.5 16.8 ± 3.9 18.8 ± 3.2
after full ChT course 63.2 ± 7.3 37.5 ± 7.2 24.4 ± 6.2* 27.3 ± 7.5*
Note. * — significant differences from the parameters of the treatment group after full ChIT course (p < 0.05).
before treatment
after treatment
t E
8 7 6 — 5 4 3 2 1 0
CD4+ Treatment group
CD4+ Control group
CD8+ Treatment group
Fig. 4. Changes in Tm / Th0 ratio, CD4+ and CD8+ subpopulations, blood of OC patients before and after treatment Table 4. Dynamics of Tcm and Tem levels, blood of OC patients, treatment and control groups
CD8+ Control group
Group of patients Treatment term Tm CD4+ Tm CD8+
Tcm, % Tem, % Tcm, % Tem, %
Treatment (n = 12) before treatment 43.0 ± 2.5 26.3 ± 3.8 24.4 ± 3.6 25.8 ± 3.3
after 2-3 ChIT cycles 39.8 ± 4.1 26.8 ± 3.3 13.3 ± 3.4* 22.6 ± 3.7
after full ChIT course 42.8 ± 3.8 28.4 ± 5.1 22.2 ± 2.9** 13.9 ± 3.6***
Control (n = 6) before treatment 42.3 ± 3.6 25.5 ± 2.8 22.5 ± 2.3 30.6 ± 4.9
after 2-3 ChT cycles 45.3 ± 4.7 23.7 ± 3.7 17.8 ± 4.0 25.3 ± 2.9
after full ChT course 43.1 ± 6.1 23.8 ± 4.7 12.6 ± 2.2* 28.7 ± 3.3
Note. * — significant differences from values seen before treatment (p < 0.05); ** —
CONCLUSIONS
Before treatment, OC patients (ascitic forms) have Tcm dominating in CD4+ subpopulation of Tm and Tem dominating in CD8+ subpopulation of Tm, which accumulate in ascitic fluid (AF). Despite the high levels of Tm in blood and AF, their function seems to be injured and therefore it is important to study the ways to correct it.
significant differences from the corresponding values of the control group (p < 0.05).
Compared to patients that received plain chemotherapy, those who had chemoimmunotherapy course with recombinant interferon-gamma showed better clinical effects: decreased volume of Th0 in blood, domination of Tcm over Tem in CD8+ Tm subpopulation. Since the like changes take place in AF too, such modulation of the tumor's immunological microenvironment can boost the clinical effect and, in particular, ensure longer recurrence-free period in OC patients.
References
1. Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther. 2009 Jun; 9 (6): 677-88. doi: 10.1517/14712590902932897
2. Golubovskaya V, Wu L. Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy. Cancers (Basel). 2016 Mar 15; 8 (3): pii: E36. doi: 10.3390/cancers8030036
3. Beckhove Ph, Feuerer M, Dolenc M, Schuetz F, Choi C Sommerfeldt N, et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest. 2004 Jul 1; 114 (1): 67-76. doi: 10.1172/JCI200420278
4. Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, et al. A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response. J Immunol. 2000 Dec 1; 165 (11): 6644-52. doi: https://doi.org/10.4049/jimmunol.165.11.6644
5. Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, et al. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+) CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 2002 Mar 15; 62 (6): 1743-50.
6. Hadrup S, Donia M, Thor Straten P. Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment. Cancer Microenviron. 2013 Aug; 6 (2): 123-33. doi: 10.1007/s12307-
012-0127-6
7. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005 Jul 5; 102 (27): 9571-6.
8. Weninger W, Crowley MA, Manjunath N, von Andrian UH. Migratory properties of naive, effector, and memory CD8 (+) T cells. J Exp Med. 2001 Oct 1; 194 (7): 953-66.
9. Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003 Mar; 4 (3): 22534.
10. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999 Oct 14; 401 (6754): 708-12.
11. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004; 22: 745-63.
12. Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol. 2014 Jan; 44 (1): 69-79. doi: 10.1002/eji.201343718
13. Perret R, Ronchese F. Memory T cells in cancer immunotherapy:
which CD8 T-cell population provides the best protection against tumours? Tissue Antigens. 2008 Sep; 72 (3): 187-94. doi: 10.1111/j.1399-0039.2008.01088.x
14. Shin H, Iwasaki A. Tissue-resident memory T cells. Immunol Rev. 2013 Sep; 255 (1): 165-81. doi: 10.1111/imr.12087
15. Zammit DJ, Turner DL, Klonowski KD, Lefrangois L, Cauley LS. Residual antigen presentation after influenza virus infection affects CD8 T cell activation and migration. Immunity. 2006 Apr; 24 (4): 439-49.
16. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature. 2012 Nov 15; 491 (7424): 463-7. doi: 10.1038/nature11522
17. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A. 2012 May 1; 109 (18): 7037-42. doi: 10.1073/pnas.1202288109
18. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011 Apr; 3 (4): 539-56. doi: 10.2217/imt.11.20
19. de Bruyn M, Wiersma VR, Wouters MC, Samplonius DF, Klip HG, Helfrich W, et al. CD20+ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. Oncoimmunology. 2015 Mar 19; 4 (4): e999536. eCollection 2015 Apr. doi: 10.1080/2162402X.2014.999536
20. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004 Jul; 4 (7): 540-50. doi: 10.1038/nrc1388
21. Berezhnaya NM, Chekhun VF. Immunologiya zlokachestvennogo rosta. Kiev: Naukova Dumka; 2005. 792 p. Russian.
22. Fidler IJ. The organ microenvironvent and cancer metastasis. Differentiation. 2002 Dec; 70 (9-10): 498-505.
23. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvirontments. Cancer Res. 2006 Jan 15; 66 (2): 605-12.
24. Ashrafyan LA, Kiselev VI, Muizhnek EL, Gerfanova EV, Antonova IB, Kuznetsov IN, et al. [Current principles of effective therapy for ovarian cancer.] Opukholi zhenskoy reproduktivnoy sistemy. 2015; 11 (2): 68-75. Russian.
25. Tyulyandin SA, Den'gina NV, Kolomiets LA, Morkhov KYu, Nechushkina VM, Pokataev IA, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniyu raka yaichnikov/ pervichnogo raka bryushiny/ raka matochnykh trub. Zlokachestvennye opukholi. 2016; (4 Suppl 2): 123-34. Russian.
26. Shmelev VA, Lichinitser MR, Abramov ME, Kuznetsov VV, Slavina EG, Kadagidze ZG. Innovatsionnyy protivoopukholevyy tsitokinovyy preparat Ingaron. Meditsinskiy alfavit. Diagnosticheskaya radiologiya i onkoterapiya. 2013; (3-4): 60-8. Russian.
27. Nerodo GA, Novikova IA, Zlatnik EYu, Ardzha AYu. [Application of Ingaron in combination with chemotherapy in patients with stage III-IV ovarian cancer]. Fundamental'nye issledovaniya. 2015; (18): 1649-54. Russian.
28. Bryuzgin VV, Platinskij LV. [The role of cytokines in the chemotherapy of malignant tumors: the practice of cytokines Refnot and Ingaron administration in advanced cancer with multiple metastases]. Sovremennaya onkologiya. 2014; 16 (1):
70-5. Russian.
29. Zlatnik EYu, Nerodo GA, Novikova IA, Bakhtin AV, Zakora GI, Selyutina ON, et al. [Molecular and cellular factors of local immunity in ascitic fluid of ovarian cancer patients]. Molekulyarnaya meditsina. 2016; 14 (3): 39-42. Russian.
30. Pollard JW. Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer. 2004 Jan; 4 (1):
71-8.
31. Kurganova EV, Tikhonova MA, Lebedeva VA, Laskavaya EG, Kovalenko VF, Ostanin AA, et al. [Regulatory T-cells in ovarian cancer]. Sibirskiy onkologicheskiy zhurnal. 2008; 30 (6): 40-5. Russian.
32. Laskavaya EG, Lebedeva VA, Narov YuI, Tikhonova MA, Kurganova EV, Ostanin AA, et al. Regulyatornye CD4+ i CD8+ kletki u bol'nykh s dobrokachestvennymi i zlokachestvennymi obrazovaniyami yaichnikov. Sibirskiy onkologicheskiy zhurnal. 2010; (Suppl 1): 67-8. Russian.
33. Chu T, Tyznik AJ, Roepke S, Berkley AM, Woodward-Davis A, Pattacini L, et al. Bystander-activated memory CD8 T cells control early pathogen load in an innate-like, NKG2D-dependent manner. Cell Rep. 2013 Mar 28; 3 (3): 701-8. doi: 10.1016/j. celrep.2013.02.020
34. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005 Dec 22; 353 (25): 2654-66.
35. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014 Jun; 20 (6): 607-15. doi: 10.1038/nm.3541
36. Nerodo GA, Zlatnik EYu, Novikova IA, Bakhtin AV, Zakora GI, Ardzha AYu, et al. Pokazateli kletochnogo immuniteta pri primenenii ingarona v kachestve terapii soprovozhdeniya pri rake yaichnikov. Rossiyskiy immunologicheskiy zhurnal. 2015; 1 (1): 141. Russian.
37. Roberts AD, Ely KH, Woodland DL. Differential contributions of central and effector memory T cells to recall responses. J Exp Med. 2005 Jul 4; 202 (1): 123-33.
Литература
1. Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther. 2009 Jun; 9 (6): 677-88. doi: 10.1517/14712590902932897
2. Golubovskaya V, Wu L. Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy. Cancers (Basel). 2016 Mar 15; 8 (3): pii: E36. doi: 10.3390/cancers8030036
3. Beckhove Ph, Feuerer M, Dolenc M, Schuetz F, Choi C, Sommerfeldt N, et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest. 2004 Jul 1; 114 (1): 67-76. doi: 10.1172/JCI200420278
4. Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, et al. A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response. J Immunol. 2000 Dec 1; 165 (11): 6644-52. doi: https://doi.org/10.4049/jimmunol.165.11.6644
5. Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, et al. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+) CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic
activity. Cancer Res. 2002 Mar 15; 62 (6): 1743-50.
6. Hadrup S, Donia M, Thor Straten P. Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment. Cancer Microenviron. 2013 Aug; 6 (2): 123-33. doi: 10.1007/s12307-012-0127-6
7. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005 Jul 5; 102 (27): 9571-6.
8. Weninger W, Crowley MA, Manjunath N, von Andrian UH. Migratory properties of naive, effector, and memory CD8 (+) T cells. J Exp Med. 2001 Oct 1; 194 (7): 953-66.
9. Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003 Mar; 4 (3): 22534.
10. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999 Oct 14; 401 (6754): 708-12.
11. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004; 22: 745-63.
12. Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol. 2014 Jan; 44 (1): 69-79. doi: 10.1002/eji.201343718
13. Perret R, Ronchese F. Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? Tissue Antigens. 2008 Sep; 72 (з): 187-94. doi: 10.1111/j.1399-0039.2008.01088.x
14. Shin H, Iwasaki A. Tissue-resident memory T cells. Immunol Rev. 2013 Sep; 255 (1): 165-81. doi: 10.1111/imr.12087
15. Zammit DJ, Turner DL, Klonowski KD, Lefrangois L, Cauley LS. Residual antigen presentation after influenza virus infection affects CD8 T cell activation and migration. Immunity. 2006 Apr; 24 (4): 439-49.
16. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature. 2012 Nov 15; 491 (7424): 463-7. doi: 10.1038/nature11522
17. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A. 2012 May 1; 109 (18): 7037-42. doi: 10.1073/pnas.1202288109
18. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011 Apr; 3 (4): 539-56. doi: 10.2217/imt.11.20
19. de Bruyn M, Wiersma VR, Wouters MC, Samplonius DF, Klip HG, Helfrich W, et al. CD20+ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. Oncoimmunology. 2015 Mar 19; 4 (4): e999536. eCollection 2015 Apr. doi: 10.1080/2162402X.2014.999536
20. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004 Jul; 4 (7): 540-50. doi: 10.1038/nrc1388
21. Бережная Н. М., Чехун В. Ф. Иммунология злокачественного роста. К.: Наукова Думка; 2005. 792 с.
22. Fidler IJ. The organ microenvironvent and cancer metastasis. Differentiation. 2002 Dec; 70 (9-10): 498-505.
23. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvirontments. Cancer Res. 2006 Jan 15; 66 (2): 605-12.
24. Ашрафян Л. А., Киселев В. И., Муйжнек Е. Л., Герфано-ва Е. В., Антонова И. Б., Кузнецов И. Н. и др. Современные принципы эффективной терапии рака яичников. Опухоли женск. репрод. системы. 2015; 11 (2): 68-75.
25. Тюляндин С. А., Деньгина Н. В., Коломиец Л. А., Мор-хов К. Ю., Нечушкина В. М., Покатаев И. А. и др. Практические рекомендации по лекарственному лечению рака яичников/ первичного рака брюшины/ рака маточных труб. Злока-честв. опухоли. 2016; (4 Спецвып. 2): 123-34.
26. Шмелев В. А., Личиницер М. Р., Абрамов М. Е., Кузнецов В. В., Славина Е. Г., Кадагидзе З. Г. Инновационный противоопухолевый цитокиновый препарат Ингарон. Мед. алфавит. Диагностич. радиол. и онкотер. 2013; (3-4): 60-8.
27. Неродо Г. А., Новикова И. А., Златник Е. Ю., Арджа А. Ю. Применение Ингарона в комплексе с химиотерапией у больных раком яичников III-IV стадий. Фундамент. исслед. 2015; 1-8: 1649-54.
28. Брюзгин В. В., Платинский Л. В. Роль цитокинов в химиотерапии злокачественных опухолей: практика применения цитокиновых препаратов. Рефнот и Ингарон при распространенных опухолевых процессах с множественными метастазами. Совр. онкол. 2014; 16 (1): 70-5.
29. Златник Е. Ю., Неродо Г. А., Новикова И. А., Бахтин А. В., За-кора Г. И., Селютина О. Н. и др. Молекулярные и клеточные факторы локального иммунитета в асцитической жидкости при раке яичников. Мол. мед. 2016; 14 (3): 39-42.
30. Pollard JW. Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer. 2004 Jan; 4 (1): 71-8.
31. Курганова Е. В., Тихонова М. А., Лебедева В. А., Ласка-вая Е. Г., Коваленко В. Ф., Останин А. А. и др. Характеристика регуляторных Т-клеток у больных раком яичников. Сибирск. онкол. журн. 2008; 30 (6): 40-5.
32. Ласкавая Е. Г., Лебедева В. А., Наров Ю. И., Тихонова М. А., Курганова Е. В., Останин А. А. и др. Регуляторные CD4+ и CD8+ клетки у больных с доброкачественными и злокачественными образованиями яичников. Сибирск. онкол. журн. 2010; (Прилож. 1): 67-8.
33. Chu T, Tyznik AJ, Roepke S, Berkley AM, Woodward-Davis A, Pattacini L, et al. Bystander-activated memory CD8 T cells control early pathogen load in an innate-like, NKG2D-dependent manner. Cell Rep. 2013 Mar 28; 3 (3): 701-8. doi: 10.1016/j. celrep.2013.02.020
34. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005 Dec 22; 353 (25): 2654-66.
35. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014 Jun; 20 (6): 607-15. doi: 10.1038/nm.3541
36. Неродо Г. А., Златник Е. Ю., Новикова И. А., Бахтин А. В., Закора Г. И., Арджа А. Ю. и др. Показатели клеточного иммунитета при применении ингарона в качестве терапии сопровождения при раке яичников. Рос. иммунол. журн. 2015; 1 (1): 141.
37. Roberts AD, Ely KH, Woodland DL. Differential contributions of central and effector memory T cells to recall responses. J Exp Med. 2005 Jul 4; 202 (1): 123-33.
